Glassman Wealth Services Sells 309 Shares of Danaher Co. (NYSE:DHR)

Glassman Wealth Services trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 16.5% in the fourth quarter, HoldingsChannel reports. The firm owned 1,561 shares of the conglomerate’s stock after selling 309 shares during the quarter. Glassman Wealth Services’ holdings in Danaher were worth $361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Wellington Management Group LLP lifted its holdings in shares of Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Danaher by 1.7% during the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after buying an additional 134,905 shares in the last quarter. Norges Bank acquired a new position in Danaher in the fourth quarter valued at about $1,752,382,000. Franklin Resources Inc. raised its stake in Danaher by 6.4% in the fourth quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock valued at $1,531,510,000 after purchasing an additional 395,498 shares in the last quarter. Finally, Flossbach Von Storch AG raised its stake in Danaher by 1.8% in the fourth quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock valued at $1,064,477,000 after purchasing an additional 82,672 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 172,540 shares of company stock worth $43,523,481. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Danaher stock traded up $1.38 during midday trading on Friday, reaching $262.78. The company’s stock had a trading volume of 2,089,037 shares, compared to its average volume of 2,351,652. The stock has a market cap of $194.64 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 4.02 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The business has a 50-day moving average price of $249.96 and a 200-day moving average price of $238.95. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $268.98.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.36 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Ratings Changes

DHR has been the subject of a number of analyst reports. Bank of America boosted their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Citigroup boosted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, KeyCorp boosted their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.